HALOZYME THERAPEUTICS, INC. (HALO)

Retention | Received a one-time performance-based restricted stock unit (PSU) grant under the 2021 Stock Plan with a target grant date fair value of $10 million.; Performance vesting is based on the average closing stock price over a 20 consecutive trading day period during a 4-year performance period.; Target share vesting percentages scale with average stock price thresholds: 50% at $115.00, 100% at $130.00, 150% at $145.00, and 200% at $170.00.; No shares will vest if the average price per share never reaches the $115.00 level during the 4-year performance period.; Subject to a time-based vesting component requiring continued employment with the Company through the fourth anniversary of the grant date.; All performance-based vested shares will be forfeited in the event of voluntary resignation or retirement prior to the final vesting date.

Severance Agreement | Eligible for 2025 annual bonus at 120% target-level individual performance.; Cash severance equal to annual base salary plus, if separation occurs in 2026, 2026 target bonus (pro-rated based on length of employment during 2026).; Equity awards vesting solely on continued service that would have vested by February 28, 2026, will vest on the Separation Date if separation occurs prior to that date.; Extension of exercise period for vested stock options to the shorter of one year post-Separation Date or the remaining option term.; Change in Control (CIC) trigger: If a CIC occurs within one year post-Separation Date, all unvested outstanding options will vest upon consummation of the CIC.; Company-paid COBRA continuation coverage for one year post-Separation Date, subject to timely election.; Benefits are contingent upon compliance with the agreement and execution of a release of claims.